Ainos, Inc. Reports Significant Revenue Decline and Net Loss in Q1 2026

Ainos, Inc. reported its financial results for the first quarter of 2026, revealing a revenue of $161, a significant decrease from $106,207 in the same period of 2025. The company attributed this decline primarily to lower sales volumes from its AI Nose programs in healthcare-adjacent applications, as it shifts focus towards industrial deployments. The cost of revenues also decreased to $763 from $18,233 year-over-year, resulting in a gross loss of $602 compared to a gross profit of $87,974 in the prior year.

Operating expenses for the quarter were $2,283,045, down 30% from $3,250,845 in Q1 2025. This reduction was driven by a 61% decrease in selling, general, and administrative expenses, which fell to $593,185 from $1,526,761. Research and development expenses remained relatively stable, totaling $1,689,860, a slight decrease from $1,724,084. The company reported a loss from operations of $2,283,647, an improvement of 28% compared to the loss of $3,162,871 in the previous year.

Ainos, Inc. recorded a net loss of $2,459,800 for the first quarter of 2026, a 25% reduction from the net loss of $3,286,022 in Q1 2025. The decrease in net loss was attributed to lower operating expenses, despite ongoing investments in product development and commercialization efforts. The company’s cash and cash equivalents increased significantly to $2,841,422 as of March 31, 2026, compared to $417,353 at the end of 2025, bolstered by proceeds from a loan agreement and an at-the-market offering.

In terms of strategic developments, Ainos has been focusing on advancing its AI Nose technology in industrial applications, particularly in semiconductor manufacturing and robotics. The company has initiated several pilot programs and partnerships aimed at expanding its market presence. As of March 31, 2026, Ainos had sold 283,336 shares under its at-the-market offering, generating net proceeds of $601,600, which will support ongoing product development and operational needs.

Looking ahead, Ainos, Inc. plans to continue its emphasis on AI Nose commercialization while managing its VELDONA® healthcare program selectively. The company anticipates that its cash reserves, along with potential revenue from ongoing projects and additional financing, will be sufficient to fund operations over the next twelve months. However, the company acknowledges the uncertainty surrounding its ability to secure necessary funding and achieve profitability, which may impact its future operations.